Tevogen Bio Agrees With CD8 to Develop, Acquire Cell Therapy Production Facility

MT Newswires Live

Apr 18, 2025

Tevogen Bio (TVGN) said Thursday it has agreed with CD 8 Technology Services to develop or acquire a facility for pre-clinical research and cell therapy production. Financial details were not disclosed.

The new facility will support both research and GMP cell therapy manufacturing, with Tevogen Bio providing the main staff and operations, the company said.

CD8 is associated with Manmohan Patel, who beneficially owns more than 5% of the company's common stock.

Tevogen Bio expects the agreement to help it avoid high upfront costs usually needed to build GMP facilities at scale, it added.

The agreement will last for 12 months at first and will automatically renew, matching the company's earlier financial forecasts, according to the company.

Shares of the company were down about 4.9% in recent trading.

Price: 0.97, Change: -0.05, Percent Change: -4.80

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2528778487"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2528778487\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2528778487?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-18 03:50","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528778487","market":"sg","top_or_hot":-1,"title":"Tevogen Bio Agrees With CD8 to Develop, Acquire Cell Therapy Production Facility","media":"MT Newswires Live","content":"<html><body><p> Tevogen Bio (TVGN) said Thursday it has agreed with CD 8 Technology Services to develop or acquire a facility for pre-clinical research and cell therapy production. Financial details were not disclosed.</p><p>The new facility will support both research and GMP cell therapy manufacturing, with Tevogen Bio providing the main staff and operations, the company said.</p><p>CD8 is associated with Manmohan Patel, who beneficially owns more than 5% of the company's common stock.</p><p>Tevogen Bio expects the agreement to help it avoid high upfront costs usually needed to build GMP facilities at scale, it added.</p><p>The agreement will last for 12 months at first and will automatically renew, matching the company's earlier financial forecasts, according to the company.</p><p>Shares of the company were down about 4.9% in recent trading.</p><p>Price: 0.97, Change: -0.05, Percent Change: -4.80</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tevogen Bio Agrees With CD8 to Develop, Acquire Cell Therapy Production Facility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTevogen Bio Agrees With CD8 to Develop, Acquire Cell Therapy Production Facility\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-04-18 03:50</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tevogen Bio (TVGN) said Thursday it has agreed with CD 8 Technology Services to develop or acquire a facility for pre-clinical research and cell therapy production. Financial details were not disclosed.</p><p>The new facility will support both research and GMP cell therapy manufacturing, with Tevogen Bio providing the main staff and operations, the company said.</p><p>CD8 is associated with Manmohan Patel, who beneficially owns more than 5% of the company's common stock.</p><p>Tevogen Bio expects the agreement to help it avoid high upfront costs usually needed to build GMP facilities at scale, it added.</p><p>The agreement will last for 12 months at first and will automatically renew, matching the company's earlier financial forecasts, according to the company.</p><p>Shares of the company were down about 4.9% in recent trading.</p><p>Price: 0.97, Change: -0.05, Percent Change: -4.80</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVGN","symbol_name":"Tevogen Bio Holdings","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2528778487","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528778487","pubTimestamp":1744919432,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tevogen Bio  said Thursday it has agreed with CD 8 Technology Services to develop or acquire a facility for pre-clinical research and cell therapy production. Financial details were not disclosed.The new facility will support both research and GMP cell therapy manufacturing, with Tevogen Bio providing the main staff and operations, the company said.CD8 is associated with Manmohan Patel, who beneficially owns more than 5% of the company's common stock.Tevogen Bio expects the agreement to help it avoid high upfront costs usually needed to build GMP facilities at scale, it added.The agreement will last for 12 months at first and will automatically renew, matching the company's earlier financial forecasts, according to the company.Shares of the company were down about 4.9% in recent trading.Price: 0.97, Change: -0.05, Percent Change: -4.80","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVGN":"Tevogen Bio Holdings","BK4139":"生物科技"},"translate_title":"Tevogen Bio同意CD8开发、收购细胞治疗生产设施","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVGN":0.9},"content_text":"Tevogen Bio (TVGN) said Thursday it has agreed with CD 8 Technology Services to develop or acquire a facility for pre-clinical research and cell therapy production. Financial details were not disclosed.The new facility will support both research and GMP cell therapy manufacturing, with Tevogen Bio providing the main staff and operations, the company said.CD8 is associated with Manmohan Patel, who beneficially owns more than 5% of the company's common stock.Tevogen Bio expects the agreement to help it avoid high upfront costs usually needed to build GMP facilities at scale, it added.The agreement will last for 12 months at first and will automatically renew, matching the company's earlier financial forecasts, according to the company.Shares of the company were down about 4.9% in recent trading.Price: 0.97, Change: -0.05, Percent Change: -4.80","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,merge","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}